Ss innovations to submit de novo application to the fda for the ssi mantra 3 surgical robotic system for multiple indications

Fort lauderdale, fla., may 08, 2025 (globe newswire) -- ss innovations international, inc. (the “company” or “ss innovations”) (nasdaq: ssii), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the company is planning to submit a de novo classification request to the u.s. food and drug administration (the “fda”) for the ssi mantra 3 surgical robotic system (the “ssi mantra 3”) in july 2025.
SSII Ratings Summary
SSII Quant Ranking